Norstella and Citeline announced Tuesday that they have agreed to merge.
Norstella is a company which offers a variety of pharmaceutical consultancy services and solutions to help guide providers and patients through the drug development life cycle.
Meanwhile, Citeline, formerly known as Pharma Intelligence, provides consultations for life sciences companies to reach pharmaceutical companies faster by giving clients necessary information from early clinical development through commercialization.
According to a press release, the two companies expect the merger to close before the end of the year once closing conditions and regulatory approvals have been settled.
The companies will put their commercial and clinical capabilities together to form an end-to-end-solution working towards a more accessible healthcare marketplace.
“Accelerating innovation and ensuring that every patient gets the therapy that they need is our North Star. By bringing clinical and commercial intelligence together — along with real-world data — the combined company will be well positioned to deliver on its mission,” said Norstella CEO Mike Gallup in a statement.
“At Citeline, our mission is to accelerate the connection of treatments to patients and patients to treatments. Ultimately, this marriage of commercial and clinical capabilities will advance the mission and enable the pharmaceutical C-suite to manage portfolio strategy like never before,” said Citeline CEO Ramsey Hashem and Executive Chair Jay Nadler in a statement.
